Companies/US/CSBR

CHAMPIONS ONCOLOGY, INC.

Income flow

Annual
CSBR 10-K Income StatementPeriod 2026-04-30Source 10-K
Pharmacology Services$57MProduct And Service Other$2MTranslational Oncology Solutions TOSLicense Revenue$764,000Revenue$59M+4% Y/YGross profit$29M-0% Y/YCost of revenue$31M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2026-04-30 · 10-K · USD
By activity
By activity$59M
  • Pharmacology Services$57M96.1%
  • Product And Service Other$2M2.6%
  • Translational Oncology Solutions TOSLicense Revenue$764,0001.3%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).13.9MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).6.1M
Stock splits
  1. 1:122015-08-12

Valuation

Trailing PE 21.7 (2025-04-30)PE trend

Fiscal PE1

PeriodEPSClosePE
2025-04-300.337.1521.7

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.